LDLR and brain neoplasm: Moreover, Zhang et al. developed a peptide-22 modified dual-targeting paclitaxel nanoparticle, leveraging peptide-22’s specific affinity for LDL-R to assist drug BBB penetration and brain tumor targeting effectively [175].